Results 71 to 80 of about 29,100 (168)

An investigation into the underlying mechanisms of risperidone-induced antinociception through the cholinergic pathway

Pharmaceutical Science Advances
Pain is a complex phenomenon involving the perception of physical discomfort caused by tissue damage in the body. Risperidone, a neuroleptic with dopamine (D2) and serotonin (5-HT2) receptor antagonistic potentials, also exhibits antinociceptive ...
Lawrence Adedayo, Victor Adesoye, Olubayode Bamidele, Idris Azeez, Oyetola Oyebanjo, Adeshina Adekeye, Saminu Samaila, Nimedia Aitokhuehi, Olusegun Adebayo, Gideon Ojo   +9 more
doaj   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies

Psychology Research and Behavior Management
Francesco Bartoli, Daniele Cavaleri, Ilaria Riboldi, Chiara Alessandra Capogrosso, Giuseppe Carr&#x00E0School of Medicine and Surgery, University of Milano-Bicocca, Monza, 20900, ItalyCorrespondence: Daniele Cavaleri, School of Medicine and Surgery ...
Bartoli F, Cavaleri D, Riboldi I, Capogrosso CA, Carrà G   +4 more
doaj  

Exposure to Antipsychotics in Youths at Clinical High Risk for Psychosis: Low VS High Doses and Their Relevance for Clinical Outcomes

Early Intervention in Psychiatry, Volume 20, Issue 4, April 2026.
ABSTRACT Introduction Predicting prognosis in subjects at Clinical High Risk for Psychosis (CHR‐P) is still challenging. In particular, there are some disregarded factors such as ongoing Antipsychotic (AP) treatment that potentially induce method errors and research bias.
Lorenzo Pelizza, Emanuela Leuci, Emanuela Quattrone, Alessandro Di Lisi, Derna Palmisano, Simona Pupo, Giuseppina Paulillo, Clara Pellegrini, Pietro Pellegrini, Marco Menchetti   +9 more
wiley   +1 more source

Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia

Journal of Intellectual Disability Research, Volume 70, Issue 4, Page 440-445, April 2026.
ABSTRACT Background Rare genetic variation can predispose individuals to the development of schizophrenia, with certain genes and copy number variants (CNVs) conferring risk at the exome/genome‐wide level. Despite this strong association, little is known about antipsychotic effectiveness and tolerability among individuals with most of these disorders ...
Mark Ainsley Colijn
wiley   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 869-878, March 2026.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

Olanzapine Attenuates the Morphine‐Induced Conditioned Place Preference: The Involvement of the D2‐Like Dopamine Receptors

Brain and Behavior, Volume 16, Issue 3, March 2026.
The results of this study demonstrated that olanzapine can inhibit morphine‐induced CPP behavior during the acquisition, expression, and extinction phases. These effects are likely mediated by the inhibition of dopamine receptors and a reduction in D2R protein expression in the HIP.
Farkhondeh Rzazzaghi‐ Firozjaei, Amineh Sadat Zahiri‐ Pour, Gholamreza Ghavipanjeh, Amir Ghaderi, Abbas Haghparast, Abolfazl Ardjmand, Hamid Reza Banafshe   +6 more
wiley   +1 more source

Effect of risperidone on proliferation and apoptosis of MC3T3-E1 cells

Brazilian Journal of Medical and Biological Research, 2019
This aim of this study was to assess the molecular mechanism of osteoporosis in schizophrenia patients with risperidone use. Here, we investigated the effects of risperidone on cellular proliferation and apoptosis of a preosteoblast cell line, MC3T3-E1 ...
Lei Zheng, Lixia Yang, Xin Zhao, Niya Long, Peifan Li, Yiming Wang   +5 more
doaj   +1 more source

Association Between D‐amino Acids in Natto (fermented soybeans) and Kidney Dysfunction

ChemFoodChem, Volume 2, Issue 1, March 2026.
XX XX ABSTRACT In this study, we examined clinical and cohort data to explore the potential renoprotective effects of natto (fermented soybeans) consumption and its relationship with D‐amino acids. In a clinical study, ten healthy adults consumed one 40‐g pack of natto three times in a single day, and plasma and urine samples were collected 1 h and 24 ...
Yusuke Nakade, Tadashi Toyama, Akinori Hara, Shigefumi Okamoto, Hiroaki Masuoka, Wataru Suda, Masashi Mita, Yuna Miyajima, Keishi Mizuguchi, Takeo Yuno, Hiroka Yamazaki, Hiroki Ohtani, Hoang Thuy Linh, Megumi Oshima, Miho Shimizu, Norihiko Sakai, Hiromasa Tsujiguchi, Hiroyuki Nakamura, Yasunori Iwata, Takashi Wada   +19 more
wiley   +1 more source

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

JCPP Advances, Volume 6, Issue 1, March 2026.
This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical symptoms of autism spectrum disorder (ASD) for children and adolescents. With limited studies available, there is a need for more high‐power studies for the use of Atomoxetine in children and adolescents with autism spectrum disorder.
Nihit Gupta, Daniel Boyes, Hunter Hanlon‐Taylor, Mayank Gupta   +3 more
wiley   +1 more source